Status:
COMPLETED
Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis
Lead Sponsor:
NYU Langone Health
Conditions:
Psoriasis
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients with PsO (subje...
Eligibility Criteria
Inclusion
- Have an active \[psoriatric plaque \>2cm
Exclusion
- History of sensitivity to study compound or any of their excipients
- Previous intolerance to PEVCO or related compounds
- Current (within 3 months of screening) treatment with DMARDs
- Current (within 3 months of screening) treatment with biologic therapies (including but limited to anti-TNF,anti-IL-17, anti-IL-12/23)
- Current antibiotic treatment (within 3 months of screening)
- current consumption of probiotics (within 3 months of screening)
- Severe hepatic impairment (eg, ac-sites and/or clinical signs of coagulopathy)
- Renal failure (eGFR ,30 or require dialysis) by history
- History of other autoimmune or inflammatory skin disease
- Current immunodeficiency state (cancer, HIV, others)
- Current immunodeficiency state (cancer, HIV, Other)
- Concern for inability of the patient to comply with study procedure, and or follow up (alcohol or drug abuse)
Key Trial Info
Start Date :
December 12 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT03409211
Start Date
December 12 2017
End Date
September 30 2019
Last Update
December 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016